You are here
Progress in acute myeloid leukemia
Clinical Lymphoma Myeloma and Leukemia
Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.
Key Words: AML Induction, Hypomethylating, FLT3.
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX
∗ Address Correspondence, Tapan M. Kadia, MD , Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 428, Houston, TX 77030, Phone: (713) 792-7305.
© 2014 Elsevier Inc., All rights reserved.